CEMTREX INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CEMTREX INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Sep 30, 2017 | $120.63M | Sep 7, 2018 |
| FY2017 | Sep 30, 2016 | $93.70M | Sep 7, 2018 |
| FY2016 | Sep 30, 2015 | $56.89M | Sep 7, 2018 |
| FY2015 | Sep 30, 2014 | $47.65M | Aug 25, 2016 |
| FY2014 | Sep 30, 2013 | $13.67M | Jan 30, 2015 |
| FY2013 | Sep 30, 2012 | $12.16M | Jun 13, 2014 |
| FY2012 | Sep 30, 2011 | $13.73M | Dec 26, 2012 |
| FY2011 | Sep 30, 2010 | $3.30M | Jan 10, 2012 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $76.49M | Dec 29, 2025 |
| FY2025 | Sep 30, 2024 | $66.86M | Dec 29, 2025 |
| FY2024 | Sep 30, 2023 | $59.37M | Dec 30, 2024 |
| FY2023 | Sep 30, 2022 | $45.03M | Dec 28, 2023 |
| FY2022 | Sep 30, 2021 | $43.13M | Dec 28, 2022 |
| FY2021 | Sep 30, 2020 | $43.52M | Jan 21, 2022 |
| FY2020 | Sep 30, 2019 | $39.27M | Jan 5, 2021 |
| FY2019 | Sep 30, 2018 | $22.64M | Jan 14, 2020 |
| FY2018 | Sep 30, 2017 | $120.63M | Jan 11, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $32.29M | Dec 29, 2025 |
| FY2025 | Sep 30, 2024 | $27.48M | Dec 29, 2025 |
| FY2024 | Sep 30, 2023 | $25.69M | Dec 30, 2024 |
| FY2023 | Sep 30, 2022 | $16.57M | Dec 28, 2023 |
| FY2022 | Sep 30, 2021 | $16.97M | Dec 28, 2022 |
| FY2021 | Sep 30, 2020 | $17.62M | Jan 21, 2022 |
| FY2020 | Sep 30, 2019 | $15.56M | Jan 5, 2021 |
| FY2019 | Sep 30, 2018 | $8.22M | Jan 14, 2020 |
| FY2018 | Sep 30, 2017 | $39.91M | Jan 11, 2019 |
| FY2017 | Sep 30, 2016 | $29.21M | Sep 7, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($28.11M) | Dec 29, 2025 |
| FY2025 | Sep 30, 2024 | ($7.23M) | Dec 29, 2025 |
| FY2024 | Sep 30, 2023 | ($9.20M) | Dec 30, 2024 |
| FY2023 | Sep 30, 2022 | ($13.02M) | Dec 28, 2023 |
| FY2022 | Sep 30, 2021 | ($7.81M) | Dec 28, 2022 |
| FY2021 | Sep 30, 2020 | ($10.47M) | Jan 21, 2022 |
| FY2020 | Sep 30, 2019 | ($22.36M) | Jan 5, 2021 |
| FY2019 | Sep 30, 2018 | ($9.24M) | Jan 14, 2020 |
| FY2018 | Sep 30, 2017 | $4.39M | Jan 11, 2019 |
| FY2017 | Sep 30, 2016 | $4.99M | Sep 7, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $509.8K | Dec 29, 2025 |
| FY2025 | Sep 30, 2024 | ($5.27M) | Dec 29, 2025 |
| FY2024 | Sep 30, 2023 | ($1.51M) | Dec 30, 2024 |
| FY2023 | Sep 30, 2022 | ($14.13M) | Dec 28, 2023 |
| FY2022 | Sep 30, 2021 | ($8.74M) | Dec 28, 2022 |
| FY2021 | Sep 30, 2020 | ($4.57M) | Jan 21, 2022 |
| FY2020 | Sep 30, 2019 | ($7.45M) | Jan 5, 2021 |
| FY2019 | Sep 30, 2018 | ($12.55M) | Jan 14, 2020 |
| FY2018 | Sep 30, 2017 | $5.12M | Jan 11, 2019 |
| FY2017 | Sep 30, 2016 | $5.06M | Sep 7, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $2.35M | Dec 29, 2025 |
| FY2025 | Sep 30, 2024 | $3.36M | Dec 29, 2025 |
| FY2024 | Sep 30, 2023 | $3.27M | Dec 30, 2024 |
| FY2023 | Sep 30, 2022 | $4.44M | Dec 28, 2023 |
| FY2022 | Sep 30, 2021 | $3.17M | Dec 28, 2022 |
| FY2021 | Sep 30, 2020 | $1.83M | Jan 21, 2022 |
| FY2020 | Sep 30, 2019 | $1.48M | Jan 5, 2021 |
| FY2019 | Sep 30, 2018 | $5.56M | Jan 14, 2020 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $28.19M | Dec 29, 2025 |
| FY2025 | Sep 30, 2024 | $27.59M | Dec 29, 2025 |
| FY2024 | Sep 30, 2023 | $22.90M | Dec 30, 2024 |
| FY2023 | Sep 30, 2022 | $21.18M | Dec 28, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $159.3K | Dec 29, 2025 |
| FY2025 | Sep 30, 2024 | ($3.95M) | Dec 29, 2025 |
| FY2024 | Sep 30, 2023 | ($2.23M) | Dec 30, 2024 |
| FY2023 | Sep 30, 2022 | ($16.09M) | Dec 28, 2023 |
| FY2022 | Sep 30, 2021 | ($10.05M) | Dec 28, 2022 |
| FY2021 | Sep 30, 2020 | ($3.79M) | Jan 21, 2022 |
| FY2020 | Sep 30, 2019 | $3.94M | Jan 5, 2021 |
| FY2019 | Sep 30, 2018 | ($2.48M) | Jan 14, 2020 |
| FY2018 | Sep 30, 2017 | $995.5K | Jan 11, 2019 |
| FY2017 | Sep 30, 2016 | $7.90M | Sep 7, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $1.93M | Dec 29, 2025 |
| FY2025 | Sep 30, 2024 | $1.30M | Dec 29, 2025 |
| FY2024 | Sep 30, 2023 | $2.76M | Dec 30, 2024 |
| FY2023 | Sep 30, 2022 | $1.77M | Dec 28, 2023 |
| FY2022 | Sep 30, 2021 | $1.07M | Dec 28, 2022 |
| FY2019 | Sep 30, 2019 | $1.66M | Jan 14, 2020 |
| FY2019 | Sep 30, 2018 | $12.21M | Jan 14, 2020 |
| FY2018 | Sep 30, 2017 | $5.68M | Jan 11, 2019 |
| FY2017 | Sep 30, 2016 | $663.8K | Sep 7, 2018 |
| FY2016 | Sep 30, 2015 | $1.52M | Sep 7, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $47.79M | Dec 29, 2025 |
| FY2025 | Sep 30, 2024 | $44.12M | Dec 29, 2025 |
| FY2024 | Sep 30, 2023 | $48.45M | Dec 30, 2024 |
| FY2023 | Sep 30, 2022 | $45.76M | Dec 28, 2023 |
| FY2022 | Sep 30, 2021 | $52.94M | Dec 28, 2022 |
| FY2021 | Sep 30, 2020 | $60.83M | Jan 21, 2022 |
| FY2020 | Sep 30, 2019 | $44.39M | Jan 5, 2021 |
| FY2019 | Sep 30, 2018 | $65.28M | Jan 14, 2020 |
| FY2018 | Sep 30, 2017 | $70.18M | Jan 11, 2019 |
| FY2017 | Sep 30, 2016 | $56.03M | Sep 7, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $39.07M | Dec 29, 2025 |
| FY2025 | Sep 30, 2024 | $39.15M | Dec 29, 2025 |
| FY2024 | Sep 30, 2023 | $40.11M | Dec 30, 2024 |
| FY2023 | Sep 30, 2022 | $31.12M | Dec 28, 2023 |
| FY2022 | Sep 30, 2021 | $29.39M | Dec 28, 2022 |
| FY2021 | Sep 30, 2020 | $31.98M | Jan 21, 2022 |
| FY2020 | Sep 30, 2019 | $22.43M | Jan 5, 2021 |
| FY2019 | Sep 30, 2018 | $30.00M | Jan 14, 2020 |
| FY2018 | Sep 30, 2017 | $31.19M | Jan 11, 2019 |
| FY2017 | Sep 30, 2016 | $40.34M | Sep 7, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $8.72M | Dec 29, 2025 |
| FY2025 | May 15, 2025 | $6.40M | Dec 29, 2025 |
| FY2025 | Jan 2, 2025 | $4.71M | Dec 29, 2025 |
| FY2025 | Sep 30, 2024 | $4.71M | Dec 29, 2025 |
| FY2025 | Sep 30, 2023 | $7.69M | Dec 29, 2025 |
| FY2024 | Sep 30, 2022 | $13.94M | Dec 30, 2024 |
| FY2023 | Sep 30, 2021 | $22.59M | Dec 28, 2023 |
| FY2022 | Sep 30, 2020 | $27.81M | Dec 28, 2022 |
| FY2021 | Sep 30, 2019 | $17.47M | Jan 21, 2022 |
| FY2020 | Sep 30, 2018 | $35.28M | Jan 5, 2021 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $3.71M | Dec 29, 2025 |
| FY2025 | Sep 30, 2024 | $3.71M | Dec 29, 2025 |
| FY2025 | Sep 30, 2023 | $4.38M | Dec 29, 2025 |
| FY2023 | Sep 30, 2022 | $3.91M | Dec 28, 2023 |
| FY2023 | Sep 30, 2021 | $7.82M | Dec 28, 2023 |
| FY2021 | Sep 30, 2020 | $7.22M | Jan 21, 2022 |
| FY2020 | Sep 30, 2019 | $4.37M | Jan 5, 2021 |
| FY2019 | Sep 30, 2018 | $3.32M | Jan 14, 2020 |
| FY2018 | Sep 30, 2017 | $3.32M | Jan 11, 2019 |
| FY2017 | Sep 30, 2016 | $918.8K | Sep 7, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($99.40M) | Dec 29, 2025 |
| FY2025 | Sep 30, 2024 | ($71.36M) | Dec 29, 2025 |
| FY2024 | Sep 30, 2023 | ($64.13M) | Dec 30, 2024 |
| FY2023 | Sep 30, 2022 | ($54.93M) | Dec 28, 2023 |
| FY2022 | Sep 30, 2021 | ($41.91M) | Dec 28, 2022 |
| FY2021 | Sep 30, 2020 | ($34.10M) | Jan 21, 2022 |
| FY2021 | Sep 30, 2019 | ($23.63M) | Jan 21, 2022 |
| FY2019 | Sep 30, 2018 | $4.26M | Jan 14, 2020 |
| FY2018 | Sep 30, 2017 | $14.42M | Jan 11, 2019 |
| FY2017 | Sep 30, 2016 | $11.42M | Sep 7, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $4.97M | Dec 29, 2025 |
| FY2025 | Sep 30, 2024 | $3.90M | Dec 29, 2025 |
| FY2024 | Sep 30, 2023 | $5.33M | Dec 30, 2024 |
| FY2023 | Sep 30, 2022 | $9.90M | Dec 28, 2023 |
| FY2022 | Sep 30, 2021 | $15.43M | Dec 28, 2022 |
| FY2021 | Sep 30, 2020 | $19.49M | Jan 21, 2022 |
| FY2020 | Sep 30, 2019 | $1.77M | Jan 5, 2021 |
| FY2019 | Sep 30, 2018 | $973.8K | Jan 14, 2020 |
| FY2018 | Sep 30, 2017 | $10.44M | Jan 11, 2019 |
| FY2017 | Sep 30, 2016 | $6.05M | Sep 7, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $13.51M | Dec 29, 2025 |
| FY2025 | Sep 30, 2024 | $18.00M | Dec 29, 2025 |
| FY2024 | Sep 30, 2023 | $24.44M | Dec 30, 2024 |
| FY2022 | Sep 30, 2022 | $20.57M | Dec 28, 2022 |
| FY2021 | Sep 30, 2021 | $16.39M | Jan 21, 2022 |
| FY2020 | Sep 30, 2020 | $19.39M | Jan 5, 2021 |
| FY2019 | Sep 30, 2019 | $5.06M | Jan 14, 2020 |
| FY2018 | Sep 30, 2018 | $9.90M | Jan 11, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Sep 30, 2021 | 0 | Jan 21, 2022 |
| FY2021 | Sep 30, 2020 | (1) | Jan 21, 2022 |
| FY2018 | Sep 30, 2018 | 0 | Jan 11, 2019 |
| FY2018 | Sep 30, 2017 | 0 | Jan 11, 2019 |
| FY2017 | Sep 30, 2016 | 0 | Sep 7, 2018 |
| FY2016 | Sep 30, 2015 | 0 | Sep 7, 2018 |
| FY2015 | Sep 30, 2014 | 0 | Aug 25, 2016 |
| FY2014 | Sep 30, 2013 | 0 | Jan 30, 2015 |
| FY2011 | Sep 30, 2011 | 0 | Jan 10, 2012 |
| FY2011 | Sep 30, 2010 | 0 | Jan 10, 2012 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Sep 30, 2021 | 0 | Jan 21, 2022 |
| FY2021 | Sep 30, 2020 | (1) | Jan 21, 2022 |
| FY2018 | Sep 30, 2018 | 0 | Jan 11, 2019 |
| FY2018 | Sep 30, 2017 | 0 | Jan 11, 2019 |
| FY2017 | Sep 30, 2016 | 0 | Sep 7, 2018 |
| FY2016 | Sep 30, 2015 | 0 | Sep 7, 2018 |
| FY2015 | Sep 30, 2014 | 0 | Aug 25, 2016 |
| FY2014 | Sep 30, 2013 | 0 | Jan 30, 2015 |
| FY2013 | Sep 30, 2012 | 0 | Jun 13, 2014 |
| FY2011 | Sep 30, 2011 | 0 | Jan 10, 2012 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 830,606 | Dec 29, 2025 |
| FY2025 | Sep 30, 2024 | 946 | Dec 29, 2025 |
| FY2024 | Sep 30, 2023 | 498 | Dec 30, 2024 |
| FY2023 | Sep 30, 2022 | 754,711 | Dec 28, 2023 |
| FY2022 | Sep 30, 2021 | 20.78M | Dec 28, 2022 |
| FY2021 | Sep 30, 2020 | 17.62M | Jan 21, 2022 |
| FY2020 | Sep 30, 2019 | 3.96M | Jan 5, 2021 |
| FY2019 | Sep 30, 2018 | 1.62M | Jan 14, 2020 |
| FY2018 | Sep 30, 2017 | 10.40M | Jan 11, 2019 |
| FY2017 | Sep 30, 2016 | 9.46M | Sep 7, 2018 |